Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856323 | 0.95 | SPHK1 (0.42) | TSHRMAPTSPHK1CYP3A4CES2 | |
| SCHEMBL26495432 | 0.93 | TSHR (0.41) | TSHRMAPTHSD17B10SPHK1CYP3A4 | |
| SCHEMBL23695904 | 0.91 | TSHR (0.39) | TSHRMAPTHSD17B10SPHK1CYP3A4 | |
| SCHEMBL21107618 | 0.91 | SPHK1 (0.42) | TSHRMAPTSPHK1CYP3A4CES2 | |
| SCHEMBL18792751 | 0.91 | TSHR (0.39) | TSHRMAPTHSD17B10SPHK1CYP3A4 | |
| SCHEMBL26373401 | 0.90 | SPHK1 (0.45) | MAPTSPHK1CES2DNM1MEN1 | |
| SCHEMBL24672966 | 0.88 | SPHK1 (0.42) | TSHRMAPTSPHK1CYP3A4CES2 | |
| SCHEMBL24508273 | 0.87 | GAA (0.35) | TSHRALDH1A1DNM1 | |
| SCHEMBL25828434 | 0.86 | KDM5A (0.34) | — | |
| SCHEMBL4142378 | 0.85 | CA1 (0.40) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885MAPT 2459/4885HSD17B10 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.